GOSS
Gossamer Bio Inc.
Company Overview
| Mkt Cap | $564.75M | Price | $0.34 |
| Volume | 7.89M | Change | -1.03% |
| P/E Ratio | -10.0 | Open | $0.35 |
| Revenue | $114.7M | Prev Close | $0.35 |
| Net Income | $-56.5M | 52W Range | $0.32 - $3.87 |
| Div Yield | N/A | Target | $3.69 |
| Overall | 26 | Value | 40 |
| Quality | 31 | Technical | 9 |
No chart data available
About Gossamer Bio Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Latest News
Gossamer Bio Investors File Securities Lawsuit Over Alleged Misstatements About Phase 3 Drug Trial
GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Analysts Allegedly Misled by Trial Claims: Levi & Korsinsky
Gossamer Bio Receives Nasdaq Minimum Bid Price Deficiency Notice
Gossamer Bio Lawsuit: Investors Allege Misleading Statements Ahead of Failed PAH Trial
Analysts Conflicted on These Healthcare Names: Gossamer Bio (GOSS) and Biogen (BIIB)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GOSS | $0.34 | -1.0% | 7.89M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |